Clinical Trials on KRAS G12C-mutated Solid Tumors, Lung Cancer in India

Total 6 results

Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
AstraZeneca
Parexel; Iqvia Pty Ltd; Medidata Solutions; CISCRP

Active, not recruiting

Durvalumab Long-Term Safety and Efficacy Study (WAVE)

Solid Tumor

Spain, United Kingdom, United States, Canada, Czechia, Poland, Romania, Thailand, Vietnam, Belgium, France, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Malaysia, Taiwan, Australia, Germany, Turkey, Ukraine, Nethe... and more
AstraZeneca
Daiichi Sankyo Co., Ltd.

Recruiting

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Canada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
Bayer

Active, not recruiting

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)

Solid Tumors Harboring NTRK Fusion

United States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
RECORDATI GROUP

Completed

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Prostate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRAS

Belgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more

Clinical Trials on KRAS G12C-mutated Solid Tumors, Lung Cancer in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations